PE20160052A1 - Composicion farmaceutica de clorhidrato de s-cetamina - Google Patents

Composicion farmaceutica de clorhidrato de s-cetamina

Info

Publication number
PE20160052A1
PE20160052A1 PE2015001997A PE2015001997A PE20160052A1 PE 20160052 A1 PE20160052 A1 PE 20160052A1 PE 2015001997 A PE2015001997 A PE 2015001997A PE 2015001997 A PE2015001997 A PE 2015001997A PE 20160052 A1 PE20160052 A1 PE 20160052A1
Authority
PE
Peru
Prior art keywords
hydrochloride
cetamine
pharmaceutical composition
formulation
depression
Prior art date
Application number
PE2015001997A
Other languages
English (en)
Inventor
Esther D G Basstanie
Johanna Bentz
Roger C A Embrechts
Nico Rudolph Niemeijer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20160052A1 publication Critical patent/PE20160052A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion esta dirigida a una formulacion acuosa de clorhidrato de S-cetamina, preferentemente para la administracion nasal, en donde la formulacion no contiene un conservante antimicrobiano, ademas es util en el tratamiento de la depresion
PE2015001997A 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-cetamina PE20160052A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791505P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20160052A1 true PE20160052A1 (es) 2016-01-28

Family

ID=50549465

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001997A PE20160052A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-cetamina
PE2019002294A PE20191796A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-ketamina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2019002294A PE20191796A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-ketamina

Country Status (26)

Country Link
US (2) US20140275277A1 (es)
EP (3) EP3498268A1 (es)
KR (3) KR20230156807A (es)
CN (3) CN111297803A (es)
AU (6) AU2014228324B2 (es)
CL (1) CL2015002733A1 (es)
CR (1) CR20150480A (es)
CY (1) CY1121928T1 (es)
DK (1) DK2968221T3 (es)
ES (1) ES2745024T3 (es)
HR (1) HRP20191477T1 (es)
HU (1) HUE045982T2 (es)
LT (1) LT2968221T (es)
ME (1) ME03465B (es)
MX (2) MX373678B (es)
MY (2) MY191332A (es)
NZ (1) NZ712270A (es)
PE (2) PE20160052A1 (es)
PH (2) PH12021552333A1 (es)
PL (1) PL2968221T3 (es)
PT (1) PT2968221T (es)
RS (1) RS59130B1 (es)
SG (3) SG11201507358VA (es)
SI (1) SI2968221T1 (es)
SM (1) SMT201900472T1 (es)
WO (1) WO2014143646A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872841B2 (en) 2013-09-13 2018-01-23 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
WO2015108985A1 (en) * 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
EP3609481A4 (en) * 2017-04-13 2021-05-26 Ovid Therapeutics Inc. DEVELOPMENTAL ENCEPHALOPATHY TREATMENT METHODS
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
HUE058320T2 (hu) 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
BR112020016500A2 (pt) 2018-02-15 2020-12-15 National University Corporation Chiba University Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス，インコーポレイティド 物質乱用の治療方法
ES3021221T3 (en) 2018-09-28 2025-05-26 Novohale Therapeutics Llc Ketamine composition for use in a method of treatment of depression by pulmonary administration
US20220062200A1 (en) * 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CA3140088A1 (en) 2019-05-31 2020-12-03 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
CN113905777B (zh) 2019-05-31 2025-06-20 赛隆制药股份公司 用于电子监督胃肠外施用药物组合物的吸入器
WO2021048638A1 (en) * 2019-09-13 2021-03-18 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
TW202135787A (zh) * 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
TWI862759B (zh) * 2019-12-20 2024-11-21 昱展新藥生技股份有限公司 氯胺酮雙羥萘酸鹽的長效注射劑型
CN114903840A (zh) * 2021-02-08 2022-08-16 四川普锐特药业有限公司 一种治疗抑郁症的低剂量r-氯胺酮经鼻药物
CN113813250B (zh) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 含氯胺酮的药物组合物及其制备方法和应用
CN116942648A (zh) 2022-04-26 2023-10-27 宜昌人福药业有限责任公司 艾司氯胺酮液体制剂及其用途
JP2025511632A (ja) 2022-04-26 2025-04-16 イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッド エスケタミン液体製剤及びその使用
EP4629989A2 (en) * 2022-12-07 2025-10-15 Freedom Biosciences, Inc. Treatment or prevention of depressive disorders through combination therapy
WO2025037252A1 (en) * 2023-08-14 2025-02-20 Javitt Daniel C Compositions and methods for treatment of chronic pain and depression
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312016A1 (de) * 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
CA2423354C (en) * 2000-09-20 2009-12-15 Lee Shahinian Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20140057988A1 (en) * 2012-08-23 2014-02-27 Stuart WEG Anxiolytic composition, formulation and method of use

Also Published As

Publication number Publication date
HRP20191477T1 (hr) 2019-12-13
LT2968221T (lt) 2019-07-25
SG10201912735TA (en) 2020-02-27
ES2745024T3 (es) 2020-02-27
SG10201802106TA (en) 2018-04-27
US20140275276A1 (en) 2014-09-18
EP2968221B1 (en) 2019-06-19
WO2014143646A1 (en) 2014-09-18
MY191332A (en) 2022-06-16
CL2015002733A1 (es) 2016-03-04
AU2023200976A1 (en) 2023-03-23
AU2019200705B2 (en) 2020-10-08
EP4309735A3 (en) 2024-04-17
MX373678B (es) 2020-06-26
MY203693A (en) 2024-07-14
AU2023200976B2 (en) 2025-03-27
AU2019200705A1 (en) 2019-02-21
KR20230156807A (ko) 2023-11-14
PH12015501957A1 (en) 2016-01-11
PL2968221T3 (pl) 2020-01-31
AU2019200696B2 (en) 2020-10-08
CN116251084A (zh) 2023-06-13
AU2019200696A1 (en) 2019-02-21
AU2019200702A1 (en) 2019-02-21
AU2014228324B2 (en) 2019-01-31
US20140275277A1 (en) 2014-09-18
SMT201900472T1 (it) 2019-09-09
DK2968221T3 (da) 2019-08-05
BR112015022970A2 (pt) 2017-07-18
BR112015022970A8 (pt) 2019-11-26
MX2015012342A (es) 2016-06-06
PH12021552333A1 (en) 2022-08-01
CN105073103A (zh) 2015-11-18
PE20191796A1 (es) 2019-12-24
ME03465B (me) 2020-01-20
AU2019200702B2 (en) 2020-10-08
EP4309735A2 (en) 2024-01-24
AU2021200072A1 (en) 2021-03-18
CN111297803A (zh) 2020-06-19
PT2968221T (pt) 2019-09-13
KR20150129023A (ko) 2015-11-18
CY1121928T1 (el) 2020-10-14
HUE045982T2 (hu) 2020-01-28
SG11201507358VA (en) 2015-10-29
EP3498268A1 (en) 2019-06-19
NZ712270A (en) 2020-02-28
RS59130B1 (sr) 2019-09-30
MX386479B (es) 2025-03-18
CR20150480A (es) 2015-10-26
EP2968221A1 (en) 2016-01-20
SI2968221T1 (sl) 2019-08-30
KR20210028278A (ko) 2021-03-11
AU2014228324A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
PE20160052A1 (es) Composicion farmaceutica de clorhidrato de s-cetamina
CR20150481A (es) Composición farmacéutica de clorhidrato de s-ketamina
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
MX375254B (es) Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis.
CO2017007316A2 (es) Formulación farmacéutica
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX381932B (es) Composicion intranasal que comprende betahistina.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
CY1122979T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX393608B (es) Profilactico o agente terapeutico para queratitis fungica.
EA201890597A1 (ru) Содержащая цинеол водная композиция для назального применения
BR112016016674A2 (pt) Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla
UA90602U (uk) Фармацевтична композиція комбінованої дії
AR101563A1 (es) Terapia de combinación de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano

Legal Events

Date Code Title Description
FG Grant, registration